Advertisement
 
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

FDA Approves Breakthrough Cancer Therapy Provenge

April 30, 2010 10:30 am | by Matthew Perrone, AP Business Writer | News | Comments

Dendreon Corp.'s Provenge, a first-of-a-kind prostate cancer treatment that uses the body's immune system to fight the disease received federal approval, offering an important alternative to more taxing treatments like chemotherapy.

TOPICS:

Simulation Software

April 30, 2010 7:08 am | Product Releases | Comments

The time-consuming scientific research behind drug discovery can now be accelerated with the launch of AMBER 11, a software tool that enables bio-scientists to harness the power of supercomputing on their desktop PC.

TOPICS:

Biomarker Panel

April 30, 2010 6:46 am | Product Releases | Comments

Beckman Coulter, Inc. introduces Solastra, a comprehensive CE-marked panel of conjugated-antibody cocktails for the characterization of hematolymphoid neoplasia by flow cytometry.

TOPICS:
Advertisement

Commentary: Will Provenge Be New Standard of Care?

April 30, 2010 6:36 am | by Fleur Pijpers, Senior Analyst, Datamonitor | News | Comments

Despite FDA approval, it remains to be seen how frequently Provenge will be used in castration-resistant prostate cancer (CRPC), according to a Datamonitor analyst.

TOPICS:

CEVEC and Aragen Sign Strategic License Agreement

April 30, 2010 6:29 am | News | Comments

CEVEC Pharmaceuticals, the developer of a novel human expression system derived from amniocytes, and Aragen Bioscience, Inc., a California-based contract research and development organization, have signed of a strategic license agreement.

TOPICS:

Mallinckrodt Baker Signs Deal With VWR International

April 30, 2010 6:17 am | News | Comments

Covidien announced that its Mallinckrodt Baker business unit has entered into a multi-year agreement with global laboratory supply company, VWR International, LLC, to distribute Mallinckrodt Baker’s J.T.Baker brand products in Eastern and Central Europe.

TOPICS:

All Immunosuppressive Drugs Carry Same Cancer Risk

April 30, 2010 6:11 am | News | Comments

Drugs taken by kidney transplant recipients to prevent organ rejection carry similar risks of cancer, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

TOPICS:

University Finds MS Biomarkers A Decade Before Symptoms

April 30, 2010 6:07 am | News | Comments

Multiple sclerosis (MS) is an equal opportunity destroyer. It attacks the central nervous system and eventually renders most patients disabled.

TOPICS:
Advertisement

FDA Approves Once-Daily Kaletra

April 30, 2010 5:56 am | News | Comments

Abbott announced that the U.S. Food and Drug Administration approved once-daily dosing of Kaletra for adult patients with HIV who have previously taken antiretroviral therapy.

TOPICS:

Provenge Vaccine Receives FDA Approval

April 30, 2010 5:45 am | by Matthew Perrone | News | Comments

A first-of-a-kind prostate cancer treatment that uses the body's immune system to fight the disease received federal approval, offering an important alternative to more taxing treatments like chemotherapy.

TOPICS:

Schwarz Pharma to Pay $22M Over False Claims

April 30, 2010 5:43 am | News | Comments

The Justice Department says Schwarz Pharma Inc. will pay $22 million for allegedly failing to disclose that two of its products did not qualify for federal health care coverage.

TOPICS:

United Therapeutics' Profits Jump 43% in Q1

April 30, 2010 5:40 am | News | Comments

United Therapeutics Corp.'s first-quarter profit increased 43 percent after the Food and Drug Administration approved two of its blood pressure drugs.

TOPICS:

BMS Profits Up 16.5% for the Quarter

April 30, 2010 5:36 am | by Linda A. Johnson | News | Comments

Drugmaker Bristol-Myers Squibb Co. reported double-digit jumps in first-quarter sales and profit, beating Wall Street expectations, but it lowered its 2010 profit forecast by a nickel due to the impact of the health care overhaul.

TOPICS:

J & J Subsidiaries Settle Topamax Case

April 30, 2010 5:33 am | by Pete Yost | News | Comments

Two subsidiaries of pharmaceutical giant Johnson & Johnson have agreed to pay more than $81 million stemming from allegedly illegal promotion of the epilepsy drug Topamax for psychiatric uses, the Justice Department announced.

TOPICS:

Drugmakers Post Higher 1st-Quarter Profits

April 30, 2010 5:30 am | by Linda A. Johnson | News | Comments

Three top drugmakers have posted healthy increases in first-quarter sales and profits, with strong sales of key drugs buoying Bristol-Myers Squibb Co., AstraZeneca LP and Sanofi-Aventis SA.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading